Molecular Imaging Program, Center for Cancer Research, National Cancer Institute , National Institutes of Health , Bethesda , Maryland 20892 , United States of America.
Bioconjug Chem. 2019 Oct 16;30(10):2624-2633. doi: 10.1021/acs.bioconjchem.9b00547. Epub 2019 Sep 23.
Regulatory T (Treg) cells play a major role in immune suppression permitting tumors to evade immune surveillance. Depletion of intratumoral Treg cells can result in tumor regression. However, systemic depletion of Tregs may also induce autoimmune adverse events. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cell-specific cancer therapy that locally kills specific cells in the tumor. Antibody-photoabsorber (IRDye700DX) conjugates (APC) are injected and bind to the tumor, and subsequent administration of NIR light to the tumor results in rapid cell death only in targeted cells. CD25-targeted NIR-PIT has been shown to induce spatially selective depletion of tumor-associated Treg cells. In this study, we compared the efficacy of an antibody fragment, anti-CD25-F(ab'), and a full antibody, anti-CD25-IgG, as agents for NIR-PIT. Tumor-bearing mice were divided into four groups: (1) no treatment; (2) anti-CD25-IgG-IR700 i.v. only; (3) anti-CD25-F(ab')-IR700 i.v. with NIR light exposure; and (4) anti-CD25-IgG-IR700 i.v. with NIR light exposure. Although both CD25-targeted NIR-PITs resulted in significant tumor growth inhibition, the anti-CD25-F(ab')-IR700 based NIR-PIT was superior to the anti-CD25-IgG-IR700 NIR-PIT. The anti-CD25-F(ab')-IR700 demonstrated faster clearance from the body than the anti-CD25-IgG-IR700. Sustained circulation of anti-CD25-IgG-IR700 may block IL-2 binding on the activated effector T-cells decreasing immune response. In conclusion, anti-CD25-F(ab') based NIR-PIT was more effective in reducing tumor growth than anti-CD25-IgG based NIR-PIT. Absence of the Fc portion of the APC leads to faster clearance and therefore promotes a superior activated T cell response in tumors.
调节性 T (Treg) 细胞在免疫抑制中发挥主要作用,使肿瘤能够逃避免疫监视。肿瘤内 Treg 细胞的耗竭可导致肿瘤消退。然而,系统性 Treg 细胞耗竭也可能引起自身免疫不良反应。近红外光免疫治疗 (NIR-PIT) 是一种新开发的细胞特异性癌症治疗方法,可局部杀死肿瘤中的特定细胞。抗体-光吸收剂 (IRDye700DX) 缀合物 (APC) 被注射并与肿瘤结合,随后向肿瘤施近红外光只会导致靶向细胞的快速细胞死亡。已显示 CD25 靶向 NIR-PIT 可诱导肿瘤相关 Treg 细胞的空间选择性耗竭。在这项研究中,我们比较了抗体片段抗 CD25-F(ab') 和完整抗体抗 CD25-IgG 作为 NIR-PIT 试剂的疗效。荷瘤小鼠分为四组:(1) 无治疗;(2) 仅静脉注射抗 CD25-IgG-IR700;(3) 静脉注射抗 CD25-F(ab')-IR700 并暴露于近红外光;(4) 静脉注射抗 CD25-IgG-IR700 并暴露于近红外光。尽管两种 CD25 靶向 NIR-PIT 均导致肿瘤生长显著抑制,但基于抗 CD25-F(ab') 的 NIR-PIT 优于基于抗 CD25-IgG-IR700 的 NIR-PIT。抗 CD25-F(ab')-IR700 从体内清除速度快于抗 CD25-IgG-IR700。抗 CD25-IgG-IR700 的持续循环可能会阻断 IL-2 与激活的效应 T 细胞结合,从而降低免疫反应。总之,基于抗 CD25-F(ab') 的 NIR-PIT 比基于抗 CD25-IgG 的 NIR-PIT 更有效地减少肿瘤生长。APC 的 Fc 部分缺失会导致更快的清除,从而促进肿瘤中激活的 T 细胞反应更好。